Axa Purchases New Stake in ARGENX SE-ADR (ARGX)

Axa purchased a new position in shares of ARGENX SE-ADR (NASDAQ:ARGX) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 150,401 shares of the company’s stock, valued at approximately $3,190,000. Axa owned approximately 0.75% of ARGENX SE-ADR as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Jennison Associates LLC bought a new position in shares of ARGENX SE-ADR during the second quarter worth $2,657,000. Franklin Resources Inc. bought a new position in shares of ARGENX SE-ADR during the second quarter worth $7,424,000. Finally, Federated Investors Inc. PA bought a new position in shares of ARGENX SE-ADR during the second quarter worth $9,545,000. 23.53% of the stock is currently owned by institutional investors.

ARGX has been the topic of a number of recent analyst reports. JMP Securities initiated coverage on shares of ARGENX SE-ADR in a research report on Monday, June 12th. They set an “outperform” rating and a $33.00 price target on the stock. Wedbush reissued an “outperform” rating on shares of ARGENX SE-ADR in a research report on Monday, June 12th. Finally, Cowen and Company initiated coverage on shares of ARGENX SE-ADR in a research report on Monday, June 12th. They set an “outperform” rating on the stock.

ARGENX SE-ADR (ARGX) opened at 21.30 on Tuesday. ARGENX SE-ADR has a 12 month low of $17.33 and a 12 month high of $25.00. The stock’s 50 day moving average is $20.81 and its 200-day moving average is $20.76. The company’s market capitalization is $572.35 million.

ILLEGAL ACTIVITY NOTICE: “Axa Purchases New Stake in ARGENX SE-ADR (ARGX)” was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at https://www.chaffeybreeze.com/2017/09/19/axa-purchases-new-stake-in-argenx-se-adr-argx.html.

ARGENX SE-ADR Profile

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Institutional Ownership by Quarter for ARGENX SE-ADR (NASDAQ:ARGX)

Receive News & Ratings for ARGENX SE-ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARGENX SE-ADR and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply